Calman Prussin
Chief Tech/Sci/R&D Officer at Knopp Neurosciences, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael E. Bozik | M | - |
Knopp Neurosciences, Inc.
 Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| Thomas Petzinger | M | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| Mary Sullivan | F | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 16 years |
| Jeff McCormick | M | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| James R. Baker | M | - |
American Board of Allergy & Immunology
| - |
| Stephen J. Pollard | M | - |
American Board of Allergy & Immunology
| - |
| Gregory T. Hebrank | M | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | 20 years |
| Donald G. Archibald | M | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| Benjamin Gomez | M | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| Shane Kovacs | M | 50 |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | - |
| Mitchell Grayson | M | - |
American Board of Allergy & Immunology
| - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 11 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Calman Prussin
- Personal Network
